Literature DB >> 1853411

Captopril improves neurologic outcome from incomplete cerebral ischemia in rats.

C Werner1, W E Hoffman, E Kochs, S F Rabito, D J Miletich.   

Abstract

We investigated the effects of the angiotensin-converting enzyme inhibitor captopril on neurologic outcome in a rat model of incomplete cerebral ischemia. Twenty male Sprague-Dawley rats were anesthetized with 70% nitrous oxide in oxygen and fentanyl (10 micrograms x kg-1 i.v. bolus, 25 micrograms x kg-1 x hr-1 i.v. continuous infusion). Animals in group 1 (n = 10) received no angiotensin-converting enzyme inhibitor while animals in group 2 (n = 10) were given 10 mg x kg-1 i.v. captopril 30 minutes prior to the ischemic period. Ischemia was produced by unilateral carotid artery ligation and hemorrhagic hypotension to 35 mm Hg for 30 minutes. Body temperature, arterial blood gases, and arterial pH were maintained constant. Neurologic outcome was evaluated every 24 hours for 3 days using a graded deficit score (0, normal; 18, stroke-related death). On the third day after ischemia, captopril significantly improved neurologic outcome (median deficit score = 4) compared with controls (median deficit score = 18) (p less than 0.05). These results suggest that reduced angiotensin II levels or increased tissue kinin concentrations may decrease ischemic brain injury.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1853411     DOI: 10.1161/01.str.22.7.910

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  9 in total

Review 1.  Angiotensin and cerebral blood flow.

Authors:  J M Saavedra; Y Nishimura
Journal:  Cell Mol Neurobiol       Date:  1999-10       Impact factor: 5.046

Review 2.  Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications.

Authors:  Juan M Saavedra; Enrique Sánchez-Lemus; Julius Benicky
Journal:  Psychoneuroendocrinology       Date:  2010-10-29       Impact factor: 4.905

3.  Treatment of traumatic brain injury in rats with N-acetyl-seryl-aspartyl-lysyl-proline.

Authors:  Yanlu Zhang; Zheng Gang Zhang; Michael Chopp; Yuling Meng; Li Zhang; Asim Mahmood; Ye Xiong
Journal:  J Neurosurg       Date:  2016-05-20       Impact factor: 5.115

4.  Elevated blood pressure aggravates intracerebral hemorrhage-induced brain injury.

Authors:  Yan-Hua Sang; Huan-Xing Su; Wu-Tian Wu; Kwok-Fai So; Raymond Tak-Fai Cheung
Journal:  J Neurotrauma       Date:  2011-10-11       Impact factor: 5.269

5.  Development of a stretch-induced neurotrauma model for medium-throughput screening in vitro: identification of rifampicin as a neuroprotectant.

Authors:  Isabel López-García; Domokos Gerő; Bartosz Szczesny; Petra Szoleczky; Gabor Olah; Katalin Módis; Kangling Zhang; Jungling Gao; Ping Wu; Lawrence C Sowers; Doug DeWitt; Donald S Prough; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2016-11-15       Impact factor: 8.739

Review 6.  Is the angiotensin II Type 2 receptor cerebroprotective?

Authors:  Albert Fournier; Jean Michel Achard; Florent Boutitie; Hakim Mazouz; Janette Mansour; Roxana Oprisiu; Leonardo Fernandez; Franz Messerli
Journal:  Curr Hypertens Rep       Date:  2004-06       Impact factor: 5.369

7.  Role of Renin-Angiotensin-Aldosterone System Inhibition in Patients Undergoing Carotid Revascularization.

Authors:  Nadin Elsayed; Jonathan Unkart; Mohammad Abdelgawwad; Isaac Naazie; Peter F Lawrence; Mahmoud B Malas
Journal:  J Am Heart Assoc       Date:  2022-08-24       Impact factor: 6.106

Review 8.  The renin-angiotensin system in the brain: possible therapeutic implications for AT(1)-receptor blockers.

Authors:  J Culman; A Blume; P Gohlke; T Unger
Journal:  J Hum Hypertens       Date:  2002-08       Impact factor: 3.012

9.  Reframing the Biological Basis of Neuroprotection Using Functional Genomics: Differentially Weighted, Time-Dependent Multifactor Pathogenesis of Human Ischemic Brain Damage.

Authors:  William A Kofke; Yue Ren; John G Augoustides; Hongzhe Li; Katherine Nathanson; Robert Siman; Qing Cheng Meng; Weiming Bu; Sukanya Yandrawatthana; Guy Kositratna; Cecilia Kim; Joseph E Bavaria
Journal:  Front Neurol       Date:  2018-06-26       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.